[Digoxin. The drug of choice for the in-utero treatment of paroxysmal supraventricular tachycardia].
Fetal tachyarrhythmia may constitute a risk for the fetus, therefore early treatment is indicate for all cases of tachydysrhythmia, with or without hydrops, in order to prevent irreversible hydrops. A case report is described of supraventricular paroxysmal tachycardia with digoxin in utero therapy in which pharmacological intervention was successful. Some comments are regarding the experience of the multidisciplinary team at Bissaya-Barreto Maternity in the treatment and orientation of fetal tachydysrhythmias.
Silva
I S
IS
Serviço de Obstetrícia, Maternidade Bissaya-Barreto, Coimbra.
Nunes
C
C
Mimoso
G
G
Castela
E
E
Mesquita
J
J
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D004077:Digoxin / Q000008:administration & dosage*; D004452:Echocardiography; D005260:Female; D005315:Fetal Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D011247:Pregnancy; D013614:Tachycardia, Paroxysmal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016216:Ultrasonography, Prenatal
D000889:Anti-Arrhythmia Agents; D004077:Digoxin
Digoxina. A droga de escolha para o tratamento in utero da taquicardia paroxística supraventricular.